AC Immune First Half 2026 Financial and Corporate Update AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, provided a corporate and financial update for the half-year ended June 30, 2026. The period saw strong advances across the Company’s pipeline, with its partnered programs generating considerable milestone payments as […]
Transcript: Isabelle Abdou: Hi, and welcome to the Optimum Perspectives podcast. I’m Isabelle Abdou, and in this latest episode, we’ll be exploring women’s health, what’s really changing in the science, the capital behind it, and what still needs to shift. To explore it, I’m joined by three leading biotech executives and a seasoned healthcare investor. […]
San Francisco, California – Yavne, Israel – July 14th, 2026 – Genopore, the next-generation proteomics company developing the first semiconductor based optical nanopore technology platform with AI/ML analysis for direct single protein molecule identification and digital quantification, today announced the appointment of life science leader Rey Mali as its new Chief Executive Officer, with immediate […]
A profoundly positive response from Anglonordic attendees with hands shaken, conversations started and potential deals in the works. The main takeaway was the benefit of it being a ‘boutique’ event, meaning everyone could make the most of the 1:1 partnering, pitch presentations, and networking breaks. Keep reading to hear more about what’s been happening this […]
Lead programme based on a first‑in‑class small‑molecule E6AP ubiquitin ligase inhibition strategy for the treatment of HPV‑positive head and neck cancer Programme has demonstrated strong in vitro and in vivo proof of mechanism, and is expected to enter the clinic in 2027 Progress is complemented with formation of world-class SAB, including leading experts in E3 […]
